Provides updated European Society of Cardiology guidelines for the diagnosis and treatment of acute and chronic heart failure.
May prompt SGLT2 inhibitor use in HFrEF; leaves open validation of HFmrEF classification in practice.
An engaging session on the newly revised European Society of Cardiology (ESC) guidelines for the diagnosis and treatment of acute and chronic heart failure (HF) was conducted on the first day of the 2021 ESC virtual congress. Chaired by Colin Baigent, Professor of Epidemiology, University of Oxford, UK, the session also explored the classification and management of HF, and addressed questions from the congress audience.
No takes yet. Share an insight, caveat, or question.
Natasha Meunier-McVey (2021) conducted a review in Heart Failure. 2021 ESC Guidelines for Heart Failure was evaluated. The 2021 ESC guidelines for heart failure introduce key updates including a Class IA recommendation for SGLT2 inhibitors in HFrEF and a revised classification for mildly reduced ejection fraction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: